EP2266647A1 — Drive mechanism for drug delivery device
Assigned to Sanofi Aventis Deutschland GmbH · Expires 2010-12-29 · 15y expired
What this patent protects
The present disclosure relates to a drug delivery device (10), in particular pen-type injectors, wherein a number or pre-set doses can be administered. In particular, the present disclosure relates to such drug delivery devices, where a user may activate the dose injection proces…
USPTO Abstract
The present disclosure relates to a drug delivery device (10), in particular pen-type injectors, wherein a number or pre-set doses can be administered. In particular, the present disclosure relates to such drug delivery devices, where a user may activate the dose injection process and wherein the user is still able to control the dose injection process even after a dose injection process has been activated. The process of injecting a dose is supported by some kind of energy storing means (22) as well as by a force to be exerted by a user. Moreover, the disclosure characterizes by a reduced amount of mechanical components.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.